Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.97 -34.49 -0.83%
Ticker Volume Price Price Delta
STOXX 50 3,175.97 -23.72 -0.74%
FTSE 100 6,674.74 -7.02 -0.11%
DAX 9,544.19 -55.90 -0.58%
Ticker Volume Price Price Delta
NIKKEI 14,522.75 -23.52 -0.16%
TOPIX 1,171.72 -2.09 -0.18%
HANG SENG 22,509.64 -221.04 -0.97%

Gilead Sciences to Present at the 31st Annual JPMorgan Healthcare Conference on Monday, January 7



  Gilead Sciences to Present at the 31st Annual JPMorgan Healthcare Conference
  on Monday, January 7

              Webcast Available Through Gilead Corporate Website

JPMorgan Healthcare Conference 2013

Business Wire

FOSTER CITY, Calif. -- January 4, 2013

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate
presentation will be webcast from the 31^st Annual JPMorgan Healthcare
Conference in San Francisco.

John C. Martin, PhD, Gilead’s Chairman and Chief Executive Officer, will
provide an overview of the company on Monday, January 7 at 3:30 p.m. Pacific
Time (6:30 p.m. Eastern Time).

To access the live webcast or a replay via the internet, log on to
www.gilead.com. Please connect to the company’s website at least 15 minutes
prior to the start of the presentation to ensure adequate time for any
software download that may be necessary to listen to the webcast. The replay
will be available for 14 days following the presentation.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and
commercializes innovative therapeutics in areas of unmet medical need. The
company’s mission is to advance the care of patients suffering from
life-threatening diseases worldwide. Headquartered in Foster City, California,
Gilead has operations in North America, Europe and Asia Pacific.

 For more information on Gilead Sciences, please visit www.gilead.com or call
   the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

Contact:

Gilead Sciences, Inc.
Patrick O’Brien, 650-522-1936
Investor Relations
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement